These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

614 related items for PubMed ID: 16860173

  • 1. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma.
    Hansel TT, Benezet O, Kafé H, Ponitz HH, Cheung D, Engelstätter R, Barnes PJ.
    Clin Ther; 2006 Jun; 28(6):906-20. PubMed ID: 16860173
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study.
    Niphadkar P, Jagannath K, Joshi JM, Awad N, Boss H, Hellbardt S, Gadgil DA.
    Clin Ther; 2005 Nov; 27(11):1752-63. PubMed ID: 16368446
    [Abstract] [Full Text] [Related]

  • 3. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K, Noonan M, Silkoff PE, Uryniak T.
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. budesonide 400 microg once daily in children with asthma.
    von Berg A, Engelstätter R, Minic P, Sréckovic M, Garcia Garcia ML, Latoś T, Vermeulen JH, Leichtl S, Hellbardt S, Bethke TD.
    Pediatr Allergy Immunol; 2007 Aug; 18(5):391-400. PubMed ID: 17617808
    [Abstract] [Full Text] [Related]

  • 5. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma.
    Vermeulen JH, Gyurkovits K, Rauer H, Engelstätter R.
    Respir Med; 2007 Oct; 101(10):2182-91. PubMed ID: 17614270
    [Abstract] [Full Text] [Related]

  • 6. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM, Boulet LP, Follows RM.
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [Abstract] [Full Text] [Related]

  • 7. Ciclesonide is more effective than budesonide in the treatment of persistent asthma.
    Ukena D, Biberger C, Steinijans V, von Behren V, Malek R, Weber HH, Beck E, Linnhoff A.
    Pulm Pharmacol Ther; 2007 Apr; 20(5):562-70. PubMed ID: 16962345
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of budesonide inhalation suspension: a nebulizable corticosteroid for persistent asthma in infants and young children.
    White MV, Cruz-Rivera M, Walton-Bowen K.
    Fam Med; 1999 May; 31(5):337-45. PubMed ID: 10407712
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma.
    Boulet LP, Drollmann A, Magyar P, Timar M, Knight A, Engelstätter R, Fabbri L.
    Respir Med; 2006 May; 100(5):785-94. PubMed ID: 16427266
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H, Orozco S, Allen A.
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [Abstract] [Full Text] [Related]

  • 11. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma.
    Pearlman DS, Berger WE, Kerwin E, Laforce C, Kundu S, Banerji D.
    J Allergy Clin Immunol; 2005 Dec; 116(6):1206-12. PubMed ID: 16337447
    [Abstract] [Full Text] [Related]

  • 12. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma.
    Bateman ED, Linnhof AE, Homik L, Freudensprung U, Smau L, Engelstätter R.
    Pulm Pharmacol Ther; 2008 Dec; 21(2):264-75. PubMed ID: 17604664
    [Abstract] [Full Text] [Related]

  • 13. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma.
    Chapman KR, Patel P, D'Urzo AD, Alexander M, Mehra S, Oedekoven C, Engelstätter R, Boulet LP.
    Allergy; 2005 Mar; 60(3):330-7. PubMed ID: 15679718
    [Abstract] [Full Text] [Related]

  • 14. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM.
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.
    Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
    [Abstract] [Full Text] [Related]

  • 16. Once-daily budesonide via Turbuhaler improves symptoms in adults with persistent asthma.
    Banov CH, Howland WC, Lumry WR.
    Ann Allergy Asthma Immunol; 2001 Jun; 86(6):627-32. PubMed ID: 11428734
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma.
    Pedersen S, Engelstätter R, Weber HJ, Hirsch S, Barkai L, Emeryk A, Weber H, Vermeulen J.
    Pulm Pharmacol Ther; 2009 Jun; 22(3):214-20. PubMed ID: 19141327
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA, MacIntyre N, Sims M, Kerwin E, Fogarty C, Noonan M, Claus R, Andrews WT.
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [Abstract] [Full Text] [Related]

  • 19. Randomized comparison of ciclesonide 160 and 640 microg/day in severe asthma.
    Bateman ED, Cheung D, Lapa e Silva J, Göhring UM, Schäfer M, Engelstätter R.
    Pulm Pharmacol Ther; 2008 Aug; 21(3):489-98. PubMed ID: 18178494
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing.
    Kerwin EM, Oppenheimer JJ, LaForce C, Parasuraman B, Miller CJ, O'Dowd L, Goldman M.
    Ann Allergy Asthma Immunol; 2009 Jul; 103(1):62-72. PubMed ID: 19663129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.